Andreas Syngros Hospital Of Venereal And Dermatological Diseases — Clinical Trial Site

54 Registered trials

21 Currently recruiting

Organisation

Andreas Syngros Hospital Of Venereal And Dermatological Diseases

Location

Athens, Greece

Identifier

ORG-100032997

Address

Dragoumi Ionos 5 I, 161 21, Greece

Departments

#2622:1st Department of Dermatology and Venereology
#3003: Dermatology Department
#7251 : Department of Dermatology- Venereology
1st Department of Dermatology - Venereology
1st Department of Dermatology
1st Department of Dermatology and Venereology
1st Department of Dermatology and Venereology NKUA
1st Department of Dermatology and Venereology.
1st Department of Dermatology and Venerology
1st Department of Dermatology-Venereology
1st Department of Dermatology-Venereology, NKUA, Medical School
1st Department of Venereal & Skin Disease
1st University Clinic of Venereal & Skin Diseases
1ST UNIVERSITY CLINIC OF VENEREAL AND SKIN DISEASES
1st University Department of Dermatology-Venereology
1st University Dermatology Clinic
1st University Dermatology Clinic
2101: University Clinic of Venereal & Skin Diseases
9202: Department of Dermatology- Venereology
A' University Clinic of Dermatology and Venereal Diseases
A' University Clinic of Dermatology and Venereal Diseases EKPA
A' University Dermatology Clinic
A’ Dermatology Clinic EKPA
A’ University Clinic of Dermatology and Venereal Diseases EKPA
Department of Dermatology
Department of Dermatology- Venereology
Department of Dermatology, Melanoma and Skin Cancer Center
Dermatology
Dermatology – Venereology Department
Dermatology and Neurology Department
Dermatology and Venereology Clinic
Dermatology and Venereology Department of N.H.S.
Dermatology Clinic
Dermatology Clinic of NHS
Dermatology-Venereology
Dermatology-Venereology Department
Dermatology-Venereology Department of NHS
Dpt. of Infectious Diseases
General Department of Dermatology and Venereology
Melanoma and Skin cancer center
University Dermatology and Venereology Clinic
University Dermatology Clinic

Clinical trials at this site (54)

Search interface

A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended

2023-503692-24-00 Cutaneous Lupus Erythematosus 5 2024-09-25
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2023-505608-43-00 Moderate to Severe Hidradenitis Suppurativa 4 2024-07-04
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended

2023-505061-82-01 Alopecia Areata 5 2024-06-17
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended

2024-511653-22-00 Cutaneous Squamous Cell Carcinoma (CSCC) 5 2020-02-12
Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Atopic Dermatitis 5 2019-01-02
A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended

2023-508337-14-00 Myositis, Dermatomyositis 4 2025-03-18
Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with… Ended

2024-514562-40-00 Hidradenitis suppurativa (HS) 4 2025-03-13
A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2024-515959-38-00 Hidradenitis Suppurativa 4 2025-03-06
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat… Ended

2023-508474-29-00 Dermatitis, Atopic 4 2024-10-30
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment… Ended

2023-509738-20-00 Plaque Psoriasis 6 2024-07-11
A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa… Ended

2023-508377-82-00 Hidradenitis Suppurativa (HS) 10 2024-06-27
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet… Ended

2023-505414-15-00 Dermatitis, Atopic 4 2024-04-10
A Phase 2 Multicenter Study to Evaluate PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations Ended

2023-503343-33-00 Active Cutaneous Lupus Erythematosus (CLE) or Systemic 4 2023-12-21
A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended

2022-502370-17-00 Hidradenitis suppurativa 4 2023-11-14
A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended

2022-501074-19-00 Hidradenitis suppurativa 10 2023-10-13
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15
A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of c… Ended

2024-518430-91-00 Acne Vulgaris 5 2023-06-13
A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended

2023-509746-35-00 Primary Discoid Lupus Erythematosus 4 2023-05-16
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25